112257-20-2 Usage
General Description
3-Aminomethyl-azetidine-1-carboxylic acid benzyl ester is a chemical compound with the molecular formula C13H18N2O2. It is an ester derivative of 3-aminomethyl-azetidine-1-carboxylic acid, and the benzyl group is attached to the carboxyl group through an ester linkage. 3-AMINOMETHYL-AZETIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used in pharmaceutical research and drug development, particularly in the synthesis of potential therapeutic agents. It has potential applications in the development of new drugs for the treatment of various medical conditions. Additionally, it may also be used as a building block in the synthesis of other organic compounds for various industrial purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 112257-20-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,2,5 and 7 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 112257-20:
(8*1)+(7*1)+(6*2)+(5*2)+(4*5)+(3*7)+(2*2)+(1*0)=82
82 % 10 = 2
So 112257-20-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H14N2O2/c12-10-6-13(7-10)11(14)15-8-9-4-2-1-3-5-9/h1-5,10H,6-8,12H2
112257-20-2Relevant articles and documents
Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides
Tarr, James C.,Wood, Michael R.,Noetzel, Meredith J.,Bertron, Jeanette L.,Weiner, Rebecca L.,Rodriguez, Alice L.,Lamsal, Atin,Byers, Frank W.,Chang, Sichen,Cho, Hyekyung P.,Jones, Carrie K.,Niswender, Colleen M.,Wood, Michael W.,Brandon, Nicholas J.,Duggan, Mark E.,Conn, P. Jeffrey,Bridges, Thomas M.,Lindsley, Craig W.
, p. 2990 - 2995 (2017/05/31)
This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The SAR to address potency, clearance, subtype selectivity, CNS exposure, and P-gp efflux are described. This work culminated in the discovery of VU6000918, which demonstrated robust efficacy in a rat amphetamine-induced hyperlocomotion reversal model at a minimum efficacious dose of 0.3?mg/kg.
